Holen Sie sich die Stockscreener-App
81.77
0.53%
0.43
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt EW?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$81.34
Offen:
$80.75
24-Stunden-Volumen:
3.33M
Relative Volume:
0.82
Marktkapitalisierung:
$48.01B
Einnahmen:
$5.69B
Nettoeinkommen (Verlust:
$1.41B
KGV:
11.77
EPS:
6.95
Netto-Cashflow:
$577.90M
1W Leistung:
+0.62%
1M Leistung:
+3.08%
6M Leistung:
+14.17%
1J Leistung:
+16.88%
1-Tages-Spanne:
$80.12
$82.05
1-Wochen-Bereich:
$80.02
$82.05
52-Wochen-Spanne:
$64.00
$83.00
Edwards Lifesciences Corp Stock (EW) Company Profile
Firmenname
Edwards Lifesciences Corp
Sektor
Branche
Telefon
(949) 250-2500
Adresse
ONE EDWARDS WAY, IRVINE, CA
Vergleichen Sie EW mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
EW
Edwards Lifesciences Corp
|
81.77 | 47.75B | 5.69B | 1.41B | 577.90M | 6.95 |
|
ABT
Abbott Laboratories
|
131.46 | 230.89B | 43.11B | 13.94B | 6.78B | 7.98 |
|
BSX
Boston Scientific Corp
|
106.66 | 156.32B | 18.49B | 2.50B | 3.49B | 1.68 |
|
SYK
Stryker Corp
|
389.94 | 149.64B | 23.82B | 2.92B | 4.02B | 7.55 |
|
MDT
Medtronic Plc
|
93.33 | 119.05B | 34.20B | 4.69B | 5.30B | 3.63 |
Edwards Lifesciences Corp Stock (EW) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-29 | Hochstufung | BTIG Research | Neutral → Buy |
| 2025-04-24 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2025-01-30 | Hochstufung | Stifel | Hold → Buy |
| 2025-01-16 | Herabstufung | Wolfe Research | Peer Perform → Underperform |
| 2024-12-16 | Hochstufung | BofA Securities | Neutral → Buy |
| 2024-10-11 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2024-09-18 | Herabstufung | Jefferies | Buy → Hold |
| 2024-07-31 | Hochstufung | Daiwa Securities | Neutral → Outperform |
| 2024-07-29 | Hochstufung | Wolfe Research | Underperform → Peer Perform |
| 2024-07-25 | Herabstufung | BofA Securities | Buy → Neutral |
| 2024-07-25 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2024-07-25 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2024-07-25 | Herabstufung | TD Cowen | Buy → Hold |
| 2024-07-25 | Herabstufung | Truist | Buy → Hold |
| 2024-05-30 | Eingeleitet | Goldman | Buy |
| 2024-05-22 | Hochstufung | Citigroup | Neutral → Buy |
| 2024-05-14 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2024-03-07 | Hochstufung | BofA Securities | Neutral → Buy |
| 2024-02-02 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2024-01-04 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2023-12-11 | Herabstufung | Citigroup | Buy → Neutral |
| 2023-11-28 | Herabstufung | Wolfe Research | Peer Perform → Underperform |
| 2023-09-26 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2023-07-19 | Eingeleitet | Robert W. Baird | Outperform |
| 2023-05-30 | Fortgesetzt | Morgan Stanley | Overweight |
| 2023-03-29 | Eingeleitet | UBS | Neutral |
| 2023-03-08 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2023-02-06 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2023-01-31 | Herabstufung | Bernstein | Outperform → Underperform |
| 2023-01-30 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2022-12-06 | Herabstufung | Stifel | Buy → Hold |
| 2022-10-28 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2022-10-26 | Eingeleitet | Mizuho | Buy |
| 2022-10-18 | Eingeleitet | Barclays | Overweight |
| 2022-10-12 | Eingeleitet | Jefferies | Buy |
| 2022-07-29 | Herabstufung | Canaccord Genuity | Buy → Hold |
| 2022-04-13 | Eingeleitet | Truist | Buy |
| 2022-04-06 | Eingeleitet | Wolfe Research | Outperform |
| 2022-03-16 | Hochstufung | Bernstein | Mkt Perform → Outperform |
| 2022-03-02 | Fortgesetzt | BofA Securities | Neutral |
| 2022-02-02 | Hochstufung | UBS | Neutral → Buy |
| 2022-01-27 | Bestätigt | Citigroup | Buy |
| 2022-01-27 | Bestätigt | Evercore ISI | Outperform |
| 2022-01-27 | Bestätigt | Raymond James | Outperform |
| 2022-01-27 | Bestätigt | Stifel | Buy |
| 2022-01-27 | Bestätigt | UBS | Neutral |
| 2021-12-17 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2021-12-15 | Hochstufung | Citigroup | Neutral → Buy |
| 2021-12-10 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2021-12-06 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2021-07-30 | Bestätigt | Canaccord Genuity | Buy |
| 2021-07-30 | Bestätigt | Deutsche Bank | Hold |
| 2021-07-30 | Bestätigt | Jefferies | Buy |
| 2021-07-30 | Bestätigt | Morgan Stanley | Overweight |
| 2021-07-30 | Bestätigt | Oppenheimer | Outperform |
| 2021-07-30 | Bestätigt | Stifel | Buy |
| 2021-07-30 | Bestätigt | UBS | Neutral |
| 2021-07-30 | Bestätigt | Wells Fargo | Equal Weight |
| 2021-05-25 | Eingeleitet | Barclays | Overweight |
| 2021-04-15 | Eingeleitet | Atlantic Equities | Neutral |
| 2021-04-05 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2020-12-16 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-12-11 | Bestätigt | Canaccord Genuity | Buy |
| 2020-09-11 | Eingeleitet | Wolfe Research | Underperform |
| 2020-04-28 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2020-04-17 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2020-03-05 | Eingeleitet | Citigroup | Buy |
| 2020-02-13 | Eingeleitet | Goldman | Neutral |
| 2020-02-06 | Fortgesetzt | BTIG Research | Neutral |
| 2020-01-10 | Eingeleitet | Oppenheimer | Outperform |
| 2020-01-02 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2019-10-24 | Bestätigt | Canaccord Genuity | Buy |
| 2019-09-23 | Eingeleitet | Piper Jaffray | Overweight |
| 2019-07-24 | Bestätigt | BofA/Merrill | Buy |
| 2019-03-18 | Bestätigt | Canaccord Genuity | Buy |
| 2019-01-18 | Hochstufung | BofA/Merrill | Neutral → Buy |
| 2019-01-03 | Eingeleitet | Deutsche Bank | Hold |
| 2018-11-28 | Eingeleitet | UBS | Neutral |
| 2018-10-16 | Eingeleitet | Barclays | Underweight |
| 2018-10-02 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2018-10-02 | Herabstufung | Guggenheim | Buy → Neutral |
Alle ansehen
Edwards Lifesciences Corp Aktie (EW) Neueste Nachrichten
Published on: 2025-09-03 02:50:15 - Newser
How to read the order book for Edwards Lifesciences CorporationJuly 2025 Opening Moves & Free Weekly Chart Analysis and Trade Guides - Newser
Can Edwards Lifesciences Corporation stock recover from recent declineTrade Entry Summary & Low Volatility Stock Suggestions - Newser
Healthcare Stocks to Watch: argenx, ICON, and Edwards Lifesciences with Long-Term Potential - AInvest
Leerink Partners Lifts Edwards Lifesciences (EW) Price Target Amid Buybacks Focus - Yahoo Finance
Edwards Lifesciences Stock: Is EW Outperforming the Healthcare Sector? - inkl
Is Edwards Lifesciences Corporation stock ready for a breakout2025 Top Decliners & Short-Term Swing Trade Alerts - Newser
Published on: 2025-09-01 12:29:31 - Newser
Using AI based signals to follow Edwards Lifesciences CorporationJuly 2025 Highlights & Fast Moving Market Watchlists - Newser
Signal strength of Edwards Lifesciences Corporation stock in tech scannersJuly 2025 Levels & Real-Time Stock Entry Alerts - Newser
What Fibonacci levels say about Edwards Lifesciences Corporation reboundJuly 2025 Sentiment & Weekly Market Pulse Alerts - Newser
Should you wait for a breakout in Edwards Lifesciences CorporationRecession Risk & Risk Controlled Stock Alerts - Newser
Forecasting Edwards Lifesciences Corporation price range with options data2025 Investor Takeaways & Weekly Chart Analysis and Guides - Newser
How institutional ownership impacts Edwards Lifesciences Corporation stockJuly 2025 Drop Watch & Fast Moving Trade Plans - Newser
Edwards Lifesciences Corporation stock trendline breakdown2025 Biggest Moves & Daily Risk Controlled Trade Plans - Newser
Analyzing net buyer seller activity in Edwards Lifesciences CorporationWeekly Profit Analysis & Free Expert Approved Momentum Trade Ideas - Newser
Is it time to cut losses on Edwards Lifesciences CorporationPortfolio Update Summary & AI Forecast for Swing Trade Picks - Newser
Edwards Lifesciences Stock: Is EW Outperforming The Healthcare Sector? - Barchart.com
Edwards Lifesciences celebrates new ESC guidelines - BioWorld MedTech
Edwards Lifesciences Corporation stock daily chart insightsDip Buying & Safe Entry Zone Tips - Newser
Edwards TAVR Gets Expanded ESC Guidelines for Severe AS Patients - Stock Titan
Edwards praises new aortic valve repair guidelines, reports positive Evoque data - MassDevice
Published on: 2025-08-29 06:42:54 - Newser
DBS Bank Adjusts Price Target on Edwards Lifesciences to $81 From $78, Maintains Hold Rating - MarketScreener
Analyzing recovery setups for Edwards Lifesciences Corporation investors2025 Buyback Activity & Weekly Chart Analysis and Guides - Newser
Building trade automation scripts for Edwards Lifesciences CorporationChart Signals & Safe Entry Momentum Tips - Newser
How Edwards Lifesciences Corporation stock reacts to Fed policy changesIndex Update & Weekly High Return Stock Forecasts - Newser
Finanzdaten der Edwards Lifesciences Corp-Aktie (EW)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.89%
1.48%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):